WAYFIND-R: Delivering a high-quality real-world data (RWD) global registry of patients diagnosed with a solid tumor and profiled with next-generation sequencing (NGS)
This poster presents the study design of WAYFIND-R, a global, prospective, longitudinal, and generalizable registry of adults with any type/stage of solid tumor profiled with next-generation sequencing (NGS) ≤3 months before enrollment. WAYFIND-R will inform on best practice for NGS-based treatment decisions by clinicians, foster global collaborations between cancer centers (enabling robust conclusions to be drawn regarding outcome data), aid understanding of disparities in patients’ access to advanced diagnostics and therapies, and ultimately drive advances in precision oncology.
{{assetTitle}}
{{assetDescription}}
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.